Elpis Biopharmaceuticals is engineering and developing multifunctional immunotherapies, which modulate disease biology with precision and safety to overcome cancer resistance. Through its proprietary mRNADisTM antibody discovery and mSCAFoldTM protein engineering platforms, Elpis is advancing a rich pipeline to treat solid tumors and hematological malignancies with the goal of improving outcomes for patients with difficult-to-treat and resistant cancers. Elpis is headquartered in Lexington, MA, with research labs in the U.S. and China.
